VERV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VERV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Verve Therapeutics's Trailing 12-Month Free Cash Flow is $-158.83 Mil, and Market Cap is $537.95 Mil. Therefore, Verve Therapeutics's FCF Yield % for today is -29.53%.
The historical rank and industry rank for Verve Therapeutics's FCF Yield % or its related term are showing as below:
During the past 5 years, the highest FCF Yield % of Verve Therapeutics was -5.44%. The lowest was -31.56%. And the median was -14.84%.
Verve Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -833.30%.
The historical data trend for Verve Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verve Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
FCF Yield % | - | - | -4.60 | -11.35 | -13.90 |
Verve Therapeutics Quarterly Data | |||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
FCF Yield % | Get a 7-Day Free Trial | -12.68 | -23.53 | -17.40 | -6.09 | -15.01 |
For the Biotechnology subindustry, Verve Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Verve Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Verve Therapeutics's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Verve Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -158.832 | / | 1142.657618 | |
= | -13.90% |
Verve Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -42.865 | * | 4 | / | 1142.657618 | |
= | -15.01% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verve Therapeutics FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Verve Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Krishna Yeshwant | director, 10 percent owner | C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043 |
Allison Dorval | officer: Chief Financial Officer | C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
Fred T. Fiedorek | officer: Chief Medical Officer | 55 BALDWIN LANE, PRINCETON NJ 08540 |
Joan Nickerson | officer: Chief Administrative Officer | C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON MA 02215 |
Andrew Bellinger | officer: Chief Scientific Officer | 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Gv 2017 Gp, L.l.c. | 10 percent owner | 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043 |
Alphabet Inc. | other: Member of 10% Group | 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043 |
Sekar Kathiresan | director, 10 percent owner, officer: Chief Executive Officer | 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Lonnel Coats | director | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Fmr Llc | 10 percent owner, other: See Remark 1 | 245 SUMMER STREET, BOSTON MA 02210 |
Alexander Cumbo | director | 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142 |
Burt A Adelman | director, 10 percent owner | DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
Andrew D. Ashe | officer: See Remarks | C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
Logos Global Management Lp | 10 percent owner | 1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129 |
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
From GuruFocus
By sperokesalga sperokesalga • 03-03-2023
By Marketwired • 09-21-2023
By sperokesalga sperokesalga • 02-14-2023
By Marketwired • 11-07-2023
By ACCESSWIRE • 11-17-2023
By PRNewswire PRNewswire • 12-27-2022
By sperokesalga sperokesalga • 05-23-2023
By PRNewswire PRNewswire • 01-04-2023
By sperokesalga sperokesalga • 05-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.